Journal: Mediators of Inflammation

Article Title: The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells

doi: 10.1155/mi/2632235

Figure Lengend Snippet: Effects of Cal on aPSC activation. (A) (Left) VDR mRNA expression in PDAC cell lines (AsPC‐1, MIA PaCa‐2, and PANC‐1) and aPSCs was determined by qRT‐PCR ( n = 3). (Right) CYP24A1 mRNA expression in PDAC or aPSCs treated with DMSO or Cal (100 nM and 48 h) was examined by qRT‐PCR ( n = 3). (B) VDR protein expression in PDAC cell lines (AsPC‐1, MIA PaCa‐2, and PANC‐1) and aPSCs was determined by western blot ( n = 3). (C) Correlation analysis between α‐SMA and VDR mRNA expression in aPSCs, with GAPDH normalization ( n = 9). (D) VDR and α‐SMA gene expression in aPSCs treated with DMSO or Cal (100 nM and 48 h) was evaluated by qRT‐PCR ( n = 3). (E) VDR and α‐SMA protein expression in aPSCs treated with DMSO or Cal (100 nM and 48 h) ( n = 4). (F) Immunocytochemistry showing α‐SMA expression in aPSCs treated with DMSO or Cal (100 nM and 48 hr) ( n = 3). (G) EZ4U assay indicating the impacts of Cal on the proliferation of aPSCs ( n = 3). (H) Transwell migration assay and (I) wound healing showing the effects of Cal on aPSCs’ migration ability ( n = 3). caPSCs, PSCs derived from pancreatic cancer; cpPSCs, PSCs derived from chronic pancreatitis; cuPSCs, culture‐activated PSCs derived from normal tissue; aPSCs, activated PSCs; HPF, high‐power field; Ctr, control group treated with DMSO. All experiments were conducted in triplicate. ns, not significant. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: Human PDAC cell lines PANC‐1 (male, American Type Culture Collection [ATCC] CRL‐1469, RRID: CVCL_0480), MIA PaCa‐2 (male, ATCC CRL‐1420, RRID: CVCL_0428), and AsPC‐1 (female, ATCC CRL‐1682, RRID: CVCL_0152) were purchased directly from the ATCC (Manassas, VA, USA) in 2015.

Techniques: Activation Assay, Expressing, Quantitative RT-PCR, Western Blot, Gene Expression, Immunocytochemistry, Transwell Migration Assay, Migration, Derivative Assay, Control

Journal: bioRxiv

Article Title: Novel combination of irreversible electroporation and allogenic chimeric antigen receptor (CAR) T-cell therapy synergizes therapeutic outcomes in a preclinical human pancreatic cancer mouse model

doi: 10.1101/2025.08.10.669537

Figure Lengend Snippet: A) In vitro tumor spheroid (TS) assay to assess the treatment response to electroporation and CAR T-cell therapy. (1) TSs were formed within a low-adherent U-bottom 96-well, (2) then moved to a 4-well rectangular plate with low- conductivity buffer to (3) deliver electroporation via parallel plate electrodes. (4) The TSs were immediately moved back into the original U-bottom well, where (5) adjuvant CAR T-cells therapy or sham was delivered. B) Live (green) and dead (red) imaging of AsPC-1 TSs at 3 hours and 72 hours after treatment for different electric field magnitudes; scale bar is 1 mm. Normalized absorbance for the XTT assay at C) 3 hours and D) 72 hours post-treatment at different electric fields; one-way ANOVA with Tukey’s post-test and correction; mean ± SD; n=3. E) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TSs over time across different electric fields. F) Normalized GFP intensity and G) TS area over time; One-way ANOVAs with Tukey’s post hoc between groups on the last timepoints (*p < 0.05, *** p < 0.001, **** p<0.0001); Multiple One-Sample Wilcoxon signed-ranked tests between that timepoint and zero (# p < 0.05); n = 3.

Article Snippet: Pan02 mouse pancreatic cancer cells (Cytion, 300501), AsPC-1 human pancreatic cancer (CRL-1682), and Jurkat immortalized human T-lymphocytes (ATCC, TIB-152) were cultured in RPMI-1640 medium (ThermoFisher, 11875093) supplemented with 10% (v/v) fetal bovine serum (Fisher Scientific, FB12999102) and 1% (v/v) 10,000 U/ml penicillin-streptomycin (Gibco, 16140122).

Techniques: In Vitro, Electroporation, Adjuvant, Imaging, XTT Assay

Journal: bioRxiv

Article Title: Novel combination of irreversible electroporation and allogenic chimeric antigen receptor (CAR) T-cell therapy synergizes therapeutic outcomes in a preclinical human pancreatic cancer mouse model

doi: 10.1101/2025.08.10.669537

Figure Lengend Snippet: A) Green fluorescent intensity of FLuc-eGFP + AsPC-1 TS, B) deep-red intensity of cell tracker- stained CAR T-cells, and C) merged image over time for the CAR T-cell only and combinatorial treatment (both). D) Measured TS area and E) normalized eGFP intensity over time; One-way ANOVAs with Tukey’s post hoc between groups on the last time points (*p < 0.05, ** p< 0.01, *** p < 0.001, **** p<0.0001); n ≥ 3. F) Comparison of deep-red intensity within the tumor spheroid over time; Two-tailed T-tests between groups at each timepoint (# p < 0.05, ## p < 0.01), n ≥ 3.

Article Snippet: Pan02 mouse pancreatic cancer cells (Cytion, 300501), AsPC-1 human pancreatic cancer (CRL-1682), and Jurkat immortalized human T-lymphocytes (ATCC, TIB-152) were cultured in RPMI-1640 medium (ThermoFisher, 11875093) supplemented with 10% (v/v) fetal bovine serum (Fisher Scientific, FB12999102) and 1% (v/v) 10,000 U/ml penicillin-streptomycin (Gibco, 16140122).

Techniques: Staining, Comparison, Two Tailed Test